{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:02:30Z","timestamp":1787702550708,"version":"build-2784847793"},"reference-count":38,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Nutr"],"published-print":{"date-parts":[[2018,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ubiquinone is a lipid antioxidant, and a novel liquid ubiquinol (a hydro-soluble, reduced form of coenzyme Q10) supplement was recently developed. The purpose of this study was to examine the levels of glucose, lipids and antioxidant capacity of type 2 diabetes patients after liquid ubiquinol supplementation. This study was designed as a randomised, double-blind, placebo-controlled trial. In all, fifty participants were randomly assigned to a placebo (<jats:italic>n<\/jats:italic> 25) or liquid ubiquinol (100 mg\/d, <jats:italic>n<\/jats:italic> 25) group, and the intervention lasted for 12 weeks. Plasma coenzyme Q10, glucose homoeostasis parameters, lipid profiles, oxidative stress and antioxidative enzyme activities were measured during the study. After 12 weeks of supplementation, glyco Hb (HbA1c) value was significantly decreased in the liquid ubiquinol group (<jats:italic>P<\/jats:italic>=0\u00b703), and subjects in the liquid ubiquinol group had significantly lower anti-glycaemic medication effect scores (MES) compared with those in the placebo group (<jats:italic>P<\/jats:italic>=0\u00b703). The catalase (<jats:italic>P<\/jats:italic>&lt;0\u00b701) and glutathione peroxidase (<jats:italic>P<\/jats:italic>=0\u00b703) activities were increased significantly after supplementation. Plasma coenzyme Q10 was correlated with the insulin level (<jats:italic>P<\/jats:italic>=0\u00b705), homoeostatic model assessment-insulin resistance (<jats:italic>P<\/jats:italic>=0\u00b707), quantitative insulin sensitivity check index (<jats:italic>P<\/jats:italic>=0\u00b703) and the anti-hyperglycaemic agents\u2019 MES (<jats:italic>P<\/jats:italic>=0\u00b703) after supplementation. Lipid profiles did not change after supplementation; however, the subjects in the placebo group had a significantly lower level of HDL-cholesterol after 12 weeks of intervention. In conclusion, oral intake of 100 mg\/d liquid ubiquinol might benefit type 2 diabetes patients by increasing antioxidant enzyme activity levels, reducing HbA1c levels and maintaining HDL-cholesterol levels.<\/jats:p>","DOI":"10.1017\/s0007114518001241","type":"journal-article","created":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T08:57:56Z","timestamp":1529917076000},"page":"57-63","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":46,"title":["Effect of liquid ubiquinol supplementation on glucose, lipids and antioxidant capacity in type 2 diabetes patients: a double-blind, randomised, placebo-controlled trial"],"prefix":"10.1017","volume":"120","author":[{"given":"Chi-Hua","family":"Yen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ju","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Jen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ting","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2018,6,25]]},"reference":[{"key":"S0007114518001241_ref29","doi-asserted-by":"publisher","DOI":"10.5925\/jnsv1954.12.293"},{"key":"S0007114518001241_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2011.06.004"},{"key":"S0007114518001241_ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(84)05016-3"},{"key":"S0007114518001241_ref4","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00095.2011"},{"key":"S0007114518001241_ref37","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000778"},{"key":"S0007114518001241_ref21","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12280"},{"key":"S0007114518001241_ref7","first-page":"150","article-title":"Coenzyme Q10: its biosynthesis and biological significance in animal organisms and in humans","volume":"59","author":"Siemieniuk","year":"2005","journal-title":"Postepy Hig Med Dosw"},{"key":"S0007114518001241_ref13","unstructured":"Mae T , Sakamoto Y , Morikawa S , et al. (2001) Pharmacetical compostition comprising coenzyme Q10. United States Patent US 6,184,255 B1, 2001."},{"key":"S0007114518001241_ref35","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet1066"},{"key":"S0007114518001241_ref15","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.73"},{"key":"S0007114518001241_ref30","first-page":"231","article-title":"The effect of coenzyme Q10 supplementation on metabolic status of type 2 diabetic patients","volume":"59","author":"Kolahdouz Mohammadi","year":"2013","journal-title":"Minerva Gastroenterol Dietol"},{"key":"S0007114518001241_ref6","doi-asserted-by":"publisher","DOI":"10.3390\/biom5010194"},{"key":"S0007114518001241_ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32833c3026"},{"key":"S0007114518001241_ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12937-016-0205-6"},{"key":"S0007114518001241_ref32","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883"},{"key":"S0007114518001241_ref11","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2891-12-142"},{"key":"S0007114518001241_ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.110.223545"},{"key":"S0007114518001241_ref1","unstructured":"World Health Organization (2016) Global report on diabetes. http:\/\/www.who.int\/diabetes\/global-report\/en\/ (accessed July 2017)."},{"key":"S0007114518001241_ref2","unstructured":"Taiwan Ministry of Health and Welfare (2017) Cause of death statistics. http:\/\/www.mohw.gov.tw\/cp-16-33598-1.html (accessed July 2017)."},{"key":"S0007114518001241_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/0925-4439(95)00028-3"},{"key":"S0007114518001241_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.02.147"},{"key":"S0007114518001241_ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e3283254549"},{"key":"S0007114518001241_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2007.03.003"},{"key":"S0007114518001241_ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-001-0760-y"},{"key":"S0007114518001241_ref19","first-page":"296","volume-title":"Healthcare (Basel)","volume":"3","author":"Shen","year":"2015"},{"key":"S0007114518001241_ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1601464"},{"key":"S0007114518001241_ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12191"},{"key":"S0007114518001241_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2010.12.006"},{"key":"S0007114518001241_ref23","first-page":"4","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy","volume":"27","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"S0007114518001241_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0271-5317(02)00402-5"},{"key":"S0007114518001241_ref24","doi-asserted-by":"publisher","DOI":"10.1021\/jf00045a019"},{"key":"S0007114518001241_ref25","first-page":"159","article-title":"Studies on the qualitative characterization of erythrocyte glutathione peroxidase","volume":"70","author":"Paglia","year":"1967","journal-title":"J Lab Clin Med"},{"key":"S0007114518001241_ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1974.tb03714.x"},{"key":"S0007114518001241_ref31","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.1.57"},{"key":"S0007114518001241_ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089169"},{"key":"S0007114518001241_ref36","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2011.35.2.101"},{"key":"S0007114518001241_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(92)90237-P"},{"key":"S0007114518001241_ref28","unstructured":"Littarru GP , Mosca F , Fattorini D , et al. (2007) Method to assay coenzyme Q10 in blood plasma or blood serum. United States Patent 7303921."}],"container-title":["British Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007114518001241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T22:56:27Z","timestamp":1555196187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007114518001241\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,25]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7,14]]}},"alternative-id":["S0007114518001241"],"URL":"https:\/\/doi.org\/10.1017\/s0007114518001241","relation":{},"ISSN":["0007-1145","1475-2662"],"issn-type":[{"value":"0007-1145","type":"print"},{"value":"1475-2662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,25]]},"assertion":[{"value":"\u00a9 The Authors 2018\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}